ÌÇÐÄÊÓƵ

ÌÇÐÄÊÓƵ Limited, a private, clinical stage biotechnology company dedicated to addressing neuropsychiatric conditions through the novel application of psychedelic medicines, announced today that Cosmo Feilding Mellen, Chief Executive Officer and Rob Conley, Chief Scientific Officer will be a panellist at Canaccord Genuity’s Symposium on New Paradigms and Treatment Approaches in Mental Health, taking place virtually on December 13th 2022. 

BPL-003 is ÌÇÐÄÊÓƵ’s patent-protected benzoate formulation of 5-MeO-DMT and is administered intranasally via an FDA-approved delivery device. In this study, BPL-003 was shown to be well-tolerated, with consistent dose delivery, highly reproducible pharmacokinetic profile and reliable induction of profound psychedelic experiences when dosed up to 12 mg in healthy participants. MHRA-approved Phase IIa studies of BPL-003 in Treatment Resistant Depression and Alcohol Use Disorder are expected to initiate in Q4 2022.

ÌÇÐÄÊÓƵ has dosed the first participant in their Phase I single-ascending dose (SAD) study of ELE-101, with top-line results expected in H1 2023. ELE-101 is a patent-protected, next-generation formulation of psilocin, the active metabolite of psilocybin, currently under clinical development for depression. ELE-101 is the second clinical-stage psychedelic compound in ÌÇÐÄÊÓƵ’s portfolio alongside BPL-003, the company’s lead candidate for upcoming MHRA-approved Phase IIa studies in depression and Alcohol Use Disorder (AUD).

Following on from last year, ÌÇÐÄÊÓƵ will again attend the Jefferies London Healthcare Conference and will hold a formal company presentation.

All equity acquisition adds short-acting psilocin candidate for broad range of indications to ÌÇÐÄÊÓƵ's portfolio of psychedelic assets. Expanded clinical pipeline will deliver multiple value inflection points over next 18 months. Phase 1 single ascending dose study of ELE-101 to initiate before the end of 2022. Lead 5-MeO-DMT formulation BPL-003 selected for upcoming Phase 2 studies in depression.

We are happy to announce the arrival of Ruth Bateson as Senior Director, Clinical Operations and Charlotte Chorley as Communications Lead.

Partnership will focus on the collection and analysis of digital biomarkers to identify signs of response and relapse in upcoming Phase 2 clinical trials ÌÇÐÄÊÓƵ aims to track and improve patient experience through an integrated, digitally-assisted treatment model

Partnership will capture behavioural and physiological signals and predictive biomarkers in ÌÇÐÄÊÓƵ’s upcoming Phase 2 clinical trials. New digital strategy aims to improve patient outcomes and safety by integrating advanced digital tools into the psychedelic treatment journey.

ÌÇÐÄÊÓƵ to collaborate with Lophora on researching New Clinical Entities (NCE’s) Broad collaboration with Lophora will further strengthen ÌÇÐÄÊÓƵ’s world class management and R&D team

ÌÇÐÄÊÓƵ Limited, a UK private company dedicated to addressing neurological and psychiatric disorders through the novel application of psychedelic medicines, today announces that Cosmo Feilding Mellen, Chief Executive Officer, will attend the 8th Annual LSX World Congress 2022.